World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
23609
World Ranking
13777
National Ranking
6992

Clinton F. Stewart publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Clinton F. Stewart sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 421 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Clinton F. Stewart D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Clinton F. Stewart sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Clinton F. Stewart is affiliated with St. Jude Children's Research Hospital in the United States. Their research spans predominantly the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on Oncology, Molecular Biology, and Genetics as subfields of study.

Their work addresses several specialized topics including:

  • Glioma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Cancer therapeutics and mechanisms
  • Lung Cancer Research Studies
  • Protein Degradation and Inhibitors
  • Advanced Breast Cancer Therapies
  • Drug Transport and Resistance Mechanisms

Stewart has published extensively, with a substantial number of papers appearing in publication venues such as:

  • Neuro-Oncology (22 publications)
  • Cancer Research (4 publications)
  • Journal of Clinical Oncology (3 publications)
  • Journal of Chromatography B (3 publications)
  • Cancer Chemotherapy and Pharmacology (3 publications)

Some recent notable papers include:

  • Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03), 2021, Journal of Clinical Oncology
  • Serial assessment of measurable residual disease in medulloblastoma liquid biopsies, 2021, Cancer Cell
  • A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study, 2021, Neuro-Oncology
  • A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies, 2020, European Journal of Cancer
  • Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib, 2020, Clinical Pharmacokinetics

Frequent collaborators with Stewart include:

  • Olivia Campagne (34 joint publications)
  • Arzu Onar-Thomas (23 joint publications)
  • Amar Gajjar (20 joint publications)
  • Giles Robinson (18 joint publications)
  • Maryam Fouladi (15 joint publications)

Best Publications

  • Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

    Amar Gajjar;Murali Chintagumpala;David Ashley;Stewart Kellie

  • Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.

    Justyna T. Romer;Hiromichi Kimura;Susan Magdaleno;Ken Sasai

  • Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

    Markos Leggas;Masashi Adachi;George L. Scheffer;Daxi Sun

  • Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy

    Paxton V. Dickson;John B. Hamner;Thomas L. Sims;Charles H. Fraga

  • Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

    Giles W. Robinson;Brent A. Orr;Gang Wu;Sridharan Gururangan

  • Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

    Peter J. Houghton;Glen S. Germain;Franklin C. Harwood;John D. Schuetz

  • Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

    Jason Fangusaro;Arzu Onar-Thomas;Tina Young Poussaint;Shengjie Wu

  • Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children

    Wayne L. Furman;Clinton F. Stewart;Catherine A. Poquette;Charles B. Pratt

  • Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

    Timothy N. Phoenix;Deanna M. Patmore;Scott Boop;Nidal Boulos

  • A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

    Anuradha Banerjee;Regina I. Jakacki;Arzu Onar-Thomas;Shengjie Wu

  • Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

    Peter J. Houghton;Pamela J. Cheshire;Leann Myers;Clinton F. Stewart

  • A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

    Brian Thiessen;Clinton Stewart;Ming Tsao;Suzanne Kamel-Reid

  • Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

    Amar Gajjar;Clinton F. Stewart;David W. Ellison;Sue Kaste

  • Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

    Clinton F. Stewart;Markos Leggas;John D. Schuetz;John C. Panetta

  • Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors

    Maryam Fouladi;Fred Laningham;Jianrong Wu;Melinda A. O'Shaughnessy

  • Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

    Eric I. Zimmerman;David C. Turner;Jassada Buaboonnam;Shuiying Hu

  • Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

    Maryam Fouladi;Julie R. Park;Clinton F. Stewart;Richard J. Gilbertson

  • Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

    William C. Zamboni;Clinton F. Stewart;Joyce Thompson;Victor M. Santana

  • Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

    Giles W Robinson;Vasilisa A Rudneva;Ivo Buchhalter;Catherine A Billups

  • Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

    Rochelle Bagatell;Wendy B. London;Lars M. Wagner;Stephan D. Voss

Frequent Co-Authors

Amar Gajjar
Amar Gajjar St. Jude Children's Research Hospital
Richard J. Gilbertson
Richard J. Gilbertson University of Cambridge
Peter J. Houghton
Peter J. Houghton The University of Texas Health Science Center at San Antonio
Larry E. Kun
Larry E. Kun St. Jude Children's Research Hospital
James M. Boyett
James M. Boyett St. Jude Children's Research Hospital
Roger J. Packer
Roger J. Packer Children’s National Health System
Martine F. Roussel
Martine F. Roussel St. Jude Children's Research Hospital
William E. Evans
William E. Evans St. Jude Children's Research Hospital
Susan M. Blaney
Susan M. Blaney Baylor College of Medicine
Thomas E. Merchant
Thomas E. Merchant St. Jude Children's Research Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in health careers beyond traditional medical school, online degrees provide flexible and affordable alternatives. Nursing professionals may consider the shortest online pmhnp programs, which offer accelerated paths to become a Psychiatric-Mental Health Nurse Practitioner (PMHNP) while continuing to work.

Aspiring leaders in health systems often pursue online healthcare administration programs, which combine management and healthcare knowledge. For advanced administration roles, an MHA is highly valued, but cost can be a concern for many students. Learning about the cost of mha degree can help you plan and select an affordable pathway.

Nursing professionals seeking leadership or faculty positions may also benefit from searching for the best dnp programs online, designed to fit busy schedules and enhance clinical expertise. Overall, these online programs can open doors to diverse healthcare careers while allowing you to balance work, study, and personal commitments.

Best Scientists Citing Clinton F. Stewart

Trending Scientists

Recently Published Articles